Global Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Therapeutics Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016" report to their offering.

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Histone Deacetylase 3 - Pipeline Review, H1 2016, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Histone Deacetylase 3 Overview
  3. Therapeutics Development
  4. Pipeline Products for Histone Deacetylase 3 - Overview
  5. Pipeline Products for Histone Deacetylase 3 - Comparative Analysis
  6. Histone Deacetylase 3 - Therapeutics under Development by Companies
  7. Histone Deacetylase 3 - Therapeutics under Investigation by Universities/Institutes
  8. Histone Deacetylase 3 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Histone Deacetylase 3 - Products under Development by Companies
  13. Histone Deacetylase 3 - Products under Investigation by Universities/Institutes
  14. Histone Deacetylase 3 - Companies Involved in Therapeutics Development
  • 4SC AG
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

For more information about this report visit http://www.researchandmarkets.com/research/gghz2x/histone

Related Topics: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716